Efficacy and safety of cryoablation combined with lenvatinib and anti-PD-1 monoclonal antibody in treatment of unresectable hepatocellular carcinoma

Teng LIU; Xiujuan CHANG; Quanwei HE; Ran XU; Yongping YANG

doi:10.12449/JCH240317

Volume 40 Issue 3

Mar. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(3): 539-549

PDF( 1848 KB)

Efficacy and safety of cryoablation combined with lenvatinib and anti-PD-1 monoclonal antibody in treatment of unresectable hepatocellular carcinoma

DOI: 10.12449/JCH240317

Division of Liver Diseases，The Fifth Medical Center of Chinese PLA General Hospital，Beijing 100039，China

Research funding:

National Science and Technology Major Project during the 13th Five-Year Plan Period (2018ZX10725506);

Beijing Natural Science Foundation (7212101)

More Information

Corresponding author: YANG Yongping， yongpingyang@hotmail.com （ORCID： 0000-0002-8307-1095）
Received Date: 2023-10-24
Accepted Date: 2023-11-22
Published Date: 2024-03-20

Abstract

Abstract

Objective To investigate whether anti-PD-1 monoclonal antibody can improve the efficacy and safety of cryoablation combined with lenvatinib in the treatment of unresectable hepatocellular carcinoma （HCC）. Methods A retrospective analysis was performed for 232 patients with unresectable HCC who were treated at The Fifth Medical Center of Chinese PLA General Hospital from January 2018 to December 2022， among whom 128 received cryoablation combined with lenvatinib （double combination） and 104 received cryoablation combined with lenvatinib and anti-PD-1 monoclonal antibody （triple combination）. Propensity score matching was performed at a ratio of 1∶1， and finally there were 86 patients in each group. The two groups were evaluated in terms of objective response rate （ORR）， disease control rate （DCR）， overall survival （OS）， progression-free survival （PFS）， and adverse events （AEs）. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups； the chi-square test was used for comparison of categorical data between two groups. Survival curves were plotted， and the Kaplan-Meier method was used to calculate the survival rate of patients in both groups， while the log-rank test was used for comparison between the two groups. The Cox regression model was used to calculate hazard ratio （HR） and 95% confidence interval （CI） and perform the univariate and multivariate analyses of influencing factors for prognosis. Results The median follow-up time was 28 months， and there were 33 deaths （38.0%） in the triple combination group and 40 deaths （46.0%） in the double combination group. Compared with the double combination group， the triple combination group had significantly higher ORR （35.6% vs 14.5%， P=0.008） and DCR （86.1% vs 64.1%， P=0.003）. OS and PFS in the triple combination group were significantly higher than those in the double combination group （P=0.045 and 0.026）. The univariate and multivariate Cox proportional-hazards regression model analyses showed that treatment regimen （HR=0.60， P=0.038） and alpha-fetoprotein level （HR=2.37， P=0.001） were independent risk factors for OS， and treatment regimen （HR=0.65， P=0.025）， diabetes mellitus （HR=1.94， P=0.005）， whether or not to have received local treatment （HR=0.63， P=0.014）， and distant metastasis （HR=0.58， P=0.009） were independent risk factors for PFS. There was no significant difference in the incidence rate of AEs between the two groups （P>0.05）. Conclusion For patients with unresectable HCC， the triple combination of cryoablation， lenvatinib， and anti-PD-1 monoclonal antibody significantly improves the treatment outcome and survival of patients compared with the double combination of cryoablation and lenvatinib， without increasing AEs， which provides a clinical basis for optimizing the treatment regimen for unresectable HCC.
- Carcinoma， Hepatocellular,
- Cryosurgery,
- Lenvatinib,
- Immune Checkpoint Inhibitors

FullText(HTML)

References(28)

References

[1]	LLOVET JM, de BAERE T, KULIK L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 5): 293- 313. DOI: 10.1038/s41575-020-00395-0.
[2]	GHAVIMI S, APFEL T, AZIMI H, et al. Management and treatment of hepatocellular carcinoma with immunotherapy: a review of current and future options[J]. J Clin Transl Hepatol, 2020, 8( 2): 168- 176. DOI: 10.14218/JCTH.2020.00001.
[3]	LIU YE, ZONG J, CHEN XJ, et al. Cryoablation combined with radiotherapy for hepatic malignancy: Five case reports[J]. World J Gastrointest Oncol, 2020, 12( 2): 237- 247. DOI: 10.4251/wjgo.v12.i2.237.
[4]	KIM R, KANG TW, DI CHA, et al. Percutaneous cryoablation for perivascular hepatocellular carcinoma: Therapeutic efficacy and vascular complications[J]. Eur Radiol, 2019, 29( 2): 654- 662. DOI: 10.1007/s00330-018-5617-6.
[5]	ABDO J, CORNELL DL, MITTAL SK, et al. Immunotherapy plus cryotherapy: potential augmented abscopal effect for advanced cancers[J]. Front Oncol, 2018, 8: 85. DOI: 10.3389/fonc.2018.00085.
[6]	CHEN LT, MARTINELLI E, CHENG AL, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO[J]. Ann Oncol, 2020, 31( 3): 334- 351. DOI: 10.1016/j.annonc.2019.12.001.
[7]	BENSON AB, D’ANGELICA MI, ABBOTT DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19( 5): 541- 565. DOI: 10.6004/jnccn.2021.0022.
[8]	SCHREIBER RD, OLD LJ, SMYTH MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion[J]. Science, 2011, 331( 6024): 1565- 1570. DOI: 10.1126/science.1203486.
[9]	CHENG AL, QIN S, IKEDA M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022, 76( 4): 862- 873. DOI: 10.1016/j.jhep.2021.11.030.
[10]	PENG Z, FAN W, ZHU B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: A Phase Ⅲ, Randomized Clinical Trial-LAUNCH)[J]. J Clin Oncol, 2023, 41( 1): 117- 127. DOI: 10.1200/JCO.22.00392.
[11]	KUDO M, UESHIMA K, IKEDA M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation(TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial[J]. Gut, 2020, 69( 8): 1492- 1501. DOI: 10.1136/gutjnl-2019-318934.
[12]	DUFFY AG, ULAHANNAN SV, MAKOROVA-RUSHER O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66( 3): 545- 551. DOI: 10.1016/j.jhep.2016.10.029.
[13]	NIU LZ, LI JL, ZENG JY, et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer[J]. World J Gastroenterol, 2013, 19( 22): 3473- 3480. DOI: 10.3748/wjg.v19.i22.3473.
[14]	YAKKALA C, DENYS A, KANDALAFT L, et al. Cryoablation and immunotherapy of cancer[J]. Curr Opin Biotechnol, 2020, 65: 60- 64. DOI: 10.1016/j.copbio.2020.01.006.
[15]	TAN J, LIU T, FAN W, et al. Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1highCD11b+ cells elimination in hepatocellular carcinoma[J]. Acta Pharm Sin B, 2023, 13( 2): 632- 647. DOI: 10.1016/j.apsb.2022.08.006.
[16]	KWAK K, YU B, LEWANDOWSKI RJ, et al. Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation[J]. Theranostics, 2022, 12( 5): 2175- 2204. DOI: 10.7150/thno.67530.
[17]	VOGEL A, MEYER T, SAPISOCHIN G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400( 10360): 1345- 1362. DOI: 10.1016/S0140-6736(22)01200-4.
[18]	LU M, ZHANG X, GAO X, et al. Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer[J]. Pharmacol Res, 2021, 174: 105829. DOI: 10.1016/j.phrs.2021.105829.
[19]	YANG XR, SUN HC, XIE Q, et al. Chinese expert guidance on overall application of lenvatinib in hepatocellular carcinoma[J]. Chin J Dig Surg, 2023, 22( 2): 167- 180. DOI: 10.3760/cma.j.cn115610-20230201-00035. 杨欣荣, 孙惠川, 谢青, 等. 仑伐替尼肝癌全病程应用中国专家指导意见[J]. 中华消化外科杂志, 2023, 22( 2): 167- 180. DOI: 10.3760/cma.j.cn115610-20230201-00035.
[20]	YANG Y, LU Y, WANG C, et al. Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma[J]. Cell Biochem Biophys, 2012, 63( 2): 159- 169. DOI: 10.1007/s12013-012-9353-2.
[21]	WANG YY, YANG X, WANG YC, et al. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma[J]. World J Gastroenterol, 2023, 29( 10): 1614- 1626. DOI: 10.3748/wjg.v29.i10.1614.
[22]	CAO F, YANG Y, SI T, et al. The efficacy of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a multicenter retrospective study[J]. Front Oncol, 2021, 11: 783480. DOI: 10.3389/fonc.2021.783480.
[23]	CAI M, HUANG W, HUANG J, et al. Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study[J]. Front Immunol, 2022, 13: 848387. DOI: 10.3389/fimmu.2022.848387.
[24]	PARK JW, KIM YJ, KIM DY, et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase Ⅲ STAH trial[J]. J Hepatol, 2019, 70( 4): 684- 691. DOI: 10.1016/j.jhep.2018.11.029.
[25]	MARINELLI B, KIM E, D’ALESSIO A, et al. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study[J]. J Immunother Cancer, 2022, 10( 6). DOI: 10.1136/jitc-2021-004205.
[26]	YUAN Y, HE W, YANG Z, et al. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study[J]. Int J Surg, 2023, 109( 5): 1222- 1230. DOI: 10.1097/JS9.0000000000000256.
[27]	CUI W, FAN W, HUANG K, et al. Large hepatocellular carcinomas: treatment with transarterial chemoembolization alone or in combination with percutaneous cryoablation[J]. Int J Hyperthermia, 2018, 35( 1): 239- 245. DOI: 10.1080/02656736.2018.1493235.
[28]	KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391( 10126): 1163- 1173. DOI: 10.1016/S0140-6736(18)30207-1.

Relative Articles

[1]	Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association， Chinese Society of Liver Cancer， Liver Study Group of Surgery Committee of Beijing Medical Association， et al. Expert consensus on the sequential surgery following conversion therapy based on the combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)[J]. Journal of Clinical Hepatology, 2025, 41(1): 30-40. doi: 10.3760/cma.j.cn113884-20240814-00245
[2]	Shichun LU. Challenges and reflections on conversion therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1738-1740. doi: 10.12449/JCH240904
[3]	Bin YAN, Gexi CAO, Yanru DENG, Ying LI, Zhanjun DONG, Wanjun BAI. Effect of amlodipine and levamlodipine on the pharmacokinetics of lenvatinib in rats and related mechanisms[J]. Journal of Clinical Hepatology, 2024, 40(11): 2246-2252. doi: 10.12449/JCH241118
[4]	Xiaomeng YAO, Keke SUN, Yunkai LIN, Hui WANG, Liwei DONG, Lei CHEN, Heping HU. Molecular mechanism of lenvatinib resistance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(12): 2524-2530. doi: 10.12449/JCH241225
[5]	Wei SUN, Xiaoyan DING, Jinglong CHEN. Efficacy and safety of anti-PD-1 monoclonal antibody combined with sorafenib or lenvatinib in treatment of patients with Child-Pugh class B unresectable hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(5): 975-981. doi: 10.12449/JCH240517
[6]	Hong NIE, Binyan ZHONG, Jian SHEN, Xiaoli ZHU. Efficacy and safety of tyrosine kinase inhibitor combined with immune checkpoint inhibitor as the second-line therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(8): 1620-1626. doi: 10.12449/JCH240818
[7]	Changwang ZHANG, Ninghan WU, Cong WANG, Zheng ZHENG, Siming GAO, Changpeng ZOU, Sujing ZHANG, Na LI. Efficacy and safety of cryoablation combined with Camrelizumab monoclonal antibody in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(6): 1169-1174. doi: 10.12449/JCH240616
[8]	Shun CHEN, Youcheng XIE, Junke WANG, Baoyin ZHAO, Jiucong ZHANG, Pan WANG, Xiaohui YU. Association between immune checkpoint inhibitor antitumor therapy and hepatitis B virus reactivation[J]. Journal of Clinical Hepatology, 2023, 39(6): 1424-1430. doi: 10.3969/j.issn.1001-5256.2023.06.027
[9]	Xingshu ZHU, Pengfei CHEN, Mengfan ZHANG, Fangzheng LI, Jinwei CHEN, Wenguang ZHANG, Xuhua DUAN, Jianzhuang REN, Xinwei HAN. Efficacy and safety of ¹²⁵I intraluminal irradiation combined with lenvatinib in treatment of progressive extrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2023, 39(10): 2406-2412. doi: 10.3969/j.issn.1001-5256.2023.10.019
[10]	Youcheng XIE, Shun CHEN, Chuyi LI, Ying ZHENG, Dong JIA, Jiucong ZHANG, Xiaohui YU. Application of immune checkpoint inhibitors in liver transplantation for patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(4): 941-947. doi: 10.3969/j.issn.1001-5256.2023.04.030
[11]	Yucheng HOU, Hongqiang ZHAO, Caoer DONG, Guangdong WU, Xuan TONG, Ang LI, Qian LU, Hong CHEN, Rui TANG. Research advances in immune checkpoint inhibitor-related cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(2): 463-468. doi: 10.3969/j.issn.1001-5256.2023.02.034
[12]	Xiaoyan DING, Wei SUN, Yanjun SHEN, Ying TENG, Yawen XU, Wendong LI, Jinglong CHEN. Efficacy and safety of lenvatinib combined with sintilimab as the second-line therapy for intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(8): 1813-1818. doi: 10.3969/j.issn.1001-5256.2022.08.018
[13]	Dan LIU, Tiantian YAO, Yuhan ZHANG, Guiqiang WANG, Yan WANG. Efficiency and safety of immune checkpoint inhibitors in cancer patients with chronic liver disease: A systematic review[J]. Journal of Clinical Hepatology, 2022, 38(11): 2457-2461. doi: 10.3969/j.issn.1001-5256.2022.11.005
[14]	Xiaomin LIU, Wei SUN, Jianying WEI, Wendong LI, Xiaoyan DING, Minghua YU, Jinglong CHEN. Efficacy and safety of lenvatinib in patients with unresectable hepatocellular carcinoma previously treated with tyrosine kinase inhibitor[J]. Journal of Clinical Hepatology, 2022, 38(6): 1323-1327. doi: 10.3969/j.issn.1001-5256.2022.06.020
[15]	Zhaoyue WANG, Lai WEI, Yuan HUANG. Advances in the application of programmed death-1/programmed death-ligand 1 inhibitors in the treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 437-443. doi: 10.3969/j.issn.1001-5256.2021.02.040
[16]	Xiaoquan JI, Aimin ZHANG, Tao ZHANG, Wengang LI, Weiping HE, Jing SUN, Xuezhang DUAN. Efficacy and safety of sequential lenvatinib therapy after stereotactic body radiotherapy in treatment of advanced primary liver cancer[J]. Journal of Clinical Hepatology, 2021, 37(9): 2120-2124. doi: 10.3969/j.issn.1001-5256.2021.09.023
[17]	Ying TENG, Xiaoyan DING, Wendong LI, Jinglong CHEN. Clinical effect of programmed cell death-1 inhibitor combined with lenvatinib in treatment of advanced primary liver cancer and related adverse events[J]. Journal of Clinical Hepatology, 2021, 37(3): 606-610. doi: 10.3969/j.issn.1001-5256.2021.03.020
[18]	Sun Tao, Ren YanQiao, Cao YanYan, Zheng ChuanSheng. Advances in immune checkpoint inhibitor combined with other treatment methods for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(6): 1386-1388. doi: 10.3969/j.issn.1001-5256.2020.06.043
[19]	Li GuangXin, Zhang Yu, Yang YanMei, Wang Yi, Li Gong. Efficacy and safety of lenvatinib for unresectable,advanced hepatocellular carcinoma in a real-world setting[J]. Journal of Clinical Hepatology, 2020, 36(10): 2266-2269. doi: 10.3969/j.issn.1001-5256.2020.10.021
[20]	Ni MingLi. Clinical effect of transcatheter arterial chemoembolization combined with argon-helium cryoablation in patients with advanced unresectable primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(1): 99-102. doi: 10.3969/j.issn.1001-5256.2015.01.021

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(6) / Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (345) PDF downloads(57)

Efficacy and safety of cryoablation combined with lenvatinib and anti-PD-1 monoclonal antibody in treatment of unresectable hepatocellular carcinoma

DOI: 10.12449/JCH240317

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Efficacy and safety of cryoablation combined with lenvatinib and anti-PD-1 monoclonal antibody in treatment of unresectable hepatocellular carcinoma

DOI: 10.12449/JCH240317

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content